In past three years, the revenue of Pfizer Inc. (NYSE:PFE)’s Global Vaccines, Oncology & Consumer Healthcare (GVOC) Segment increased considerably in the past three years, i.e., from 2012-2014. This segment of the company is solely involved in development as well as commercialization of oncology products, vaccines as well as healthcare products for consumers. Every division of the GVOC segment in Pfizer has its own separate venture at the global level. Also, every business has its own specialization, as is indicative from the name. The market approach and science of these three divisions is also segregated and different.
The revenue and its impact
The revenue of Pfizer’s GVOC from 2012-2014 was $28.2 billion ($8.9 billion, $9.2 billion and $10.1 billion in 2012, 13 and 14 respectively). There was an adverse effect of the currency on GVOC.
Despite this, the overall revenue for Global Vaccines segment increased to $4.4 billion in 2014, by 13%. This happened mainly because of Pfizer’s drugs belonging to Prevnar family, which is the higher revenue contributor to the company.
The oncology saw the 12% increase in revenue in the previous year and it reached $2.2 billion. Inlyta and Xalkori, the recent drugs being launched by the company increased the revenue in this segment. Also Bosulif was unveiled in the U.S. The healthcare of the company increased in 2014 to $3.4 billion, by 3%. Nexium 24HR launch in the U.S. along with the vitamin supplements was the main reason for this increase.
There are other companies in this sector which contribute 7.80% of this total Health Care SPDR (ETF) (NYSEARCA:XLV). These companies include Bristol-Myers Squibb Co (NYSE:BMY), Eli Lilly and Co (NYSE:LLY), Abbott Laboratories (NYSE:ABT), and Novartis AG (ADR) (NYSE:NVS).
The costs of Pfizer in GVOC segment
In this segment Pfizer’s gross profit margin climbed from 79.7% to 80.3% from 2012 to 2014, respectively.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of USmarketsDaily.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: